A Johnson & Johnson spokesperson said there are no quality issues regarding the actual medication Simponi. Rather, a defect in the device did not allow the full dose to be delivered for self-injection. The defect was detected in Germany during quality assurance checks. In total, 165 U.S. units have been recalled, according to the report.
Read the news report about the Johnson & Johnson recall.
Read other coverage about Johnson & Johnson:
– Smith & Nephew Shares Jump After Rejecting Johnson & Johnson Acquisition
– Alphatec Holdings Names Former Johnson & Johnson CFO as New CFO
– FDA Sends Johnson & Johnson Letter of Warning
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
